57441-74-4

Basic information

• Product Name: 6,7-DIMETHOXY-1-INDANONE
• Synonyms: 6,7-DIMETHOXY-1-INDANONE;6,7-Dimethoxyindan-1-one;6,7-DiMethoxy-2,3-dihydro-1H-inden-1-one;2,3-Dihydro-6,7-dimethoxy-1H-inden-1-one
• CAS NO: 57441-74-4
• Molecular Formula: C₁₁H₁₂O₃
• Molecular Weight: 192.21
• Mol File: 57441-74-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 40-43 °C
• Boiling Point: 341.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.179±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 6,7-DIMETHOXY-1-INDANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIMETHOXY-1-INDANONE(57441-74-4)
• EPA Substance Registry System: 6,7-DIMETHOXY-1-INDANONE(57441-74-4)

Safety Data

• Hazardous Substances Data: 57441-74-4(Hazardous Substances Data)

Usage

Description

6,7-Dimethoxy-1-indanone is an organic compound characterized by its indanone core structure, which features a fused six-membered and five-membered ring system. It is further distinguished by the presence of two methoxy groups at the 6th and 7th positions. 6,7-DIMETHOXY-1-INDANONE is known for its potential applications in various fields due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
6,7-Dimethoxy-1-indanone is used as a key intermediate in the synthesis of new chalcone derivatives. These derivatives have been identified as inhibitors of human P-glycoprotein, a protein that plays a crucial role in multidrug resistance in cancer cells. By inhibiting this protein, chalcone derivatives can potentially enhance the effectiveness of chemotherapeutic drugs and overcome resistance in cancer treatment.

Upstream product

• 50-00-0 formaldehyd 
• 1521-38-6 2,3-dimethoxybenzoic acid 
• 108-59-8 malonic acid dimethyl ester 
• 18028-29-0 4-bromo-6,7-dimethoxy-1-indanone 
• 412336-00-6 7,8-dimethoxy-1-oxo-1H-isothiochromene-3-carboxylic acid 
• 5653-52-1 2-carboxy-3,4-dimethoxy-cinnamic acid 
• 2107-70-2 3,4-methoxycinnamic acid 
• 64-17-5 ethanol 
• 87896-90-0 dihydroxy-indanone 
• 74-88-4 methyl iodide 
• 857771-65-4 3-(2-carboxy-3,4-dimethoxy-phenyl)-propionic acid 

Downstream Products

• 53762-45-1 6-cyanomethyl-2,3-dimethoxy-benzoic acid 
• 18028-29-0 4-bromo-6,7-dimethoxy-1-indanone 

Relevant articles and documents

Synthesis method of 1-indanone compounds

The present invention provides a synthesis method of 1-indanone compounds. The method comprises the following steps: adding benzoic acid compounds, dimethyl malonate, paraformaldehyde, a rhodium catalyst and an alkali to an organic solvent, heating under a nitrogen gas condition to carry out a reaction, and after the reaction is complete, carrying out post-treatment to obtain the 1-indanone compounds. The provided synthesis method of the 1-indanone compounds is simple and convenient to operate, the substrate is cheap and easy to obtain, wide in universality and good in functional group compatibility, and a simple and efficient method is provided for synthesizing indanone derivatives with diversified structures.

Synthesis of 1-indanones by intramolecular Friedel-Crafts reaction of 3-arylpropionic acids catalyzed by Tb(OTf)3

Intramolecular Friedel-Crafts acylation reaction of 3-arylpropionic acids was efficiently catalyzed by Tb(OTf)3 at 250°C to give 1-indanones. Even deactivated 3-arylpropionic acids with halogen atoms on the aromatic ring can be cyclized in moderation to good yields.

Tricyclic compounds, their production and use

A compound of the formula: STR1 wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.